200 results about "Kidney tubules" patented technology

An early-onset method and kit for detecting renal tubular cell injury, using NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and thus readily detected in urine following tubular cell injury. NGAL protein expression was mainly detected in the proximal tubule cells, which resembled a secreted protein with a punctate distribution in the cytoplasm. Apparent NGAL in urine correlates with the amount and duration of renal ischemia and nephrotoxicemia and is a diagnostic feature of tubular cell injury and renal failure. NGAL detection is also a useful marker for monitoring nephrotoxic side effects of drugs or other therapeutic agents.

A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

The invention provides an in-vitro detection method of human cystatin C. The method adopts a magnetic particle separation chemiluminescence immunoassay technology which is a product integrating an enzyme labeling technology, a magnetic particle separation technology and a chemiluminescence detection technology and has the advantages of high sensitivity, good specificity, good repetitiveness, and the like. The method can be used for measuring the content of cystatin C in the serum, the plasma and the urine of a person, and the indexes are mainly used for clinically evaluating the renal function and mainly used for monitoring the filtration rate of glomerulus, the renal tubular dysfunction and various secondary nephropathies.

Glossy ganoderma as a traditional Chinese medicine is called immortal grass since ancient times and known as the ability to treat various diseases; a pair of lingzhiol A optical enantiomers is purified from ganoderma lucidum, and the lingzhiol A optical enantiomers have obvious effects on inhibiting rat renal mesangial cell strains induced by high glucose to generate reactive oxide species, IL-6, fibronectin and IV type collagen, and also can obviously inhibit the phosphorylation of the renal tubular epithelial cell Smad3 induced by TGF-beta1, so that the application prospect of the compound in preparation of medicines for treating diabetic nephropathy and chronic nephropathy is shown.

Described herein are organoids comprising admixtures of selected bioactive primary renal cells and a bioactive cell population, e.g., an endothelial cell populations, e.g. HUVEC cells, and methods of treating a subject in need thereof with such organoids. Further, the isolated renal cells, which may include tubular and erythropoietin {EPO}-producing kidney cell populations, and / or the endothelial cell populations may be of autologous, syngeneic, allogeneic or xenogeneic origin, or any combination thereof. Further provided are methods of treating a subject in need with the organoids.

A nephropathy-associated gene which encodes a transcription repressor; and a nonhuman transgenic animal suffering from nephropathy which is constructed by transferring the above gene and allows the observation of increases in urinary volume, urinary albumin and urinary NAG, pyelectasis, enlargement in kidney tubule and glomerular swelling at the early stage and the following sclerosis.

It is an object of the present invention to provide a combination of a functional assessment of renal function together with biomarker results in order to improve assessment of patient at risk of or having, an acute kidney injury. A loop diuretic such as furosemide inhibits luminal active chloride transport throughout the thick ascending limb of Henle, thereby preventing sodium reabsorption and resulting in natriuresis and increased urine flow. Loop diuretic-induced increases in urine output might be a method to assess the integrity of the renal tubular function in the setting of early AKI, and so a kidney's response, or lack thereof, to a diuretic challenge as a clinical assessment of tubular function can identify patients with severe tubular injury before it is clinically apparent (e.g. a rise in creatinine).

Biomarker signatures were identified which can be used to diagnose or predict kidney or liver toxicity and more specifically renal tubular toxicity as a consequence of disease or drug treatment.

The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and / or monitoring of treatment regimens.

The invention relates to a traditional Chinese medicinal compositional medicine for treating contrast-induced nephropathy (CIN), which is prepared from the following raw medicinal materials in parts by weight: 1-3 parts of prepared Radix Et Rhizoma Rhei and 1 parts of Ligusticum chuanxiong. The invention also provides application of the traditional Chinese medicinal compositional medicine. The compositional medicine of the invention has the advantages that the formulation of the traditional Chinese medicinal compositional medicine of the invention meets the traditional Chinese medicinal principle of assistant and guide; through the confirmation of pharmacodynamics experiments, the renal function of CIN model rat can be effectively protected, and the effect of controlling CIN is shown; mechanism study finds that the renal function of the rat can be protected by inhibiting the expression of caspase3 and then antagonizing apoptosis of rat renal tubular epithelial cells; and the compositional medicine has fewer number of bulk pharmaceutical chemicals, low toxic adverse effects and low cost, and is suitable for long-term administration. The new traditional Chinese medicinal composition for treating CIN is provided by the invention, and has good application prospects.

A method of assessing kidney function in a human subject to aid in the diagnosis of renal tubule diseases or conditions specific to a particular renal tubule region, comprises contacting a urine sample from said subject with a panel of capture molecules, each capture molecule being capable of binding to a specific biomarker from at least one of the four major regions of the renal tubule, in particular the proximal, distal, collecting duct and loop of Henle regions, the detection of one or more biomarkers in the urine sample being indicative of damage in a corresponding region of the renal tubule. The method facilitates inter alia the non-invasive detection of renal tubule damage and serves as a prognostic method to determine the level of tubule damage and monitor the effectiveness of therapeutic treatment.

Disclosed are renal tissues and arrays thereof that include a layer of renal interstitial tissue, the renal interstitial tissue comprising renal fibroblasts and endothelial cells; and a layer of renal epithelial tissue, the renal epithelial tissue comprising renal tubular epithelial cells, the renal epithelial tissue in contact with the layer of renal interstitial tissue to form a three-dimensional, engineered, biological renal tissue. Also disclosed are methods of fabricating and using the same.

The invention provides a new purpose of a DNA tetrahedron in preparation of a medicine capable of treating renal injury, and belongs to the field of nucleic acid medicines. The invention proves that the DNA tetrahedron can repair injured renal tubular epithelial cells, and discloses the new purpose of the DNA tetrahedron used for treating the renal injury. Since the DNA tetrahedron has high biocompatibility and few medicines used for treating the renal injury are in the presence at present, the new purpose disclosed by the invention has a good application value.

The invention discloses a nano-enzyme diagnosis and treatment agent for acute kidney injury as well as a preparation method and application of the nano-enzyme diagnosis and treatment agent. The nano-enzyme diagnosis and treatment agent comprises noble metal nano-particles and surface ligands combined on the surfaces of the noble metal nano-particles. The nano-enzyme diagnosis and treatment agent comprises a surface ligand and noble metal nanoparticles protected by the surface ligand. The nano-enzyme diagnosis and treatment agent disclosed by the invention has an ultra-small size, can be effectively enriched in the kidney of a mouse, can remove a large amount of active oxygen or active nitrogen in a renal canaliculus to relieve and treat acute kidney injury induced by glycerol or cis-platinum, and can be used as a contrast agent for computed tomography and photoacoustic imaging technologies. In addition, the nano-enzyme diagnosis and treatment agent has a good treatment effect and alsohas excellent biocompatibility and biosafety.

The invention relates to a demonstration model for simulating the pathological change of acute glomerulonephritis. The invention belongs to a medical teaching device, and particularly relates to a teaching aid for demonstrating the pathological change of acute glomerulonephritis. The teaching aid mainly comprises a heart model, an afferent glomerular arteriole model, a glomerular capillary u-shaped loop model, a mesangial region saccus model, an efferent glomerular arteriole model, a renal capsule model, a renal tubule model, a urine pool and a blood pool, thereby forming a model system for demonstrating the pathological clinical correlation of acute glomerulonephritis. The device is simple in structure and convenient to operate, and has high visuality and understandability in the teaching process. Besides, the device facilitates students to foster the observation and problem analysis capabilities.

The invention discloses a convolutional neural network-based kidney tubule epithelial cell automatic detection method and belongs to the image processing field. According to the convolutional neural network-based kidney tubule epithelial cell automatic detection method, cells are screened initially based on the morphological features of kidney tubule epithelial cells; identification is carried out based on a convolutional neural network; and therefore, automatic detection of the kidney tubule epithelial cells can be realized, and defects such as low detection efficiency and susceptibility to subjective factors can be avoided, and efficient and convenient detection can be realized. The number of visible components in medical microscopic images is large, and the backgrounds of the medical microscopic images are complex, and as a result, medical personnel tend to generate visual fatigue in a long-term high-intensity working condition, and the possibility of misjudgment or omitted judgment in microscopic examination is large. According to the convolutional neural network-based kidney tubule epithelial cell automatic detection method of the invention, the automatic detection of the kidney tubule epithelial cells can be realized based on digital image processing technologies, and therefore, detection accuracy can be improved, the risk of treatment delay of patients can be lowered, and the labor intensity of the medical personnel can be reduced.

The invention discloses a nano-enzyme diagnosis and treatment agent for acute kidney injury and a preparation method and use of nano-enzyme diagnosis and treatment agent. The nano-enzyme diagnosis andtreatment agent comprises Prussian blue nano-particles and surface ligands combined on surfaces of the Prussian blue nano-particles. The nano-enzyme diagnosis and treatment agent comprises the surface ligands (CS) and the Prussian blue nanoparticles (PB NZs) protected by the surface ligands. The nano-enzyme diagnosis and treatment agent has an ultra-small size, can be effectively enriched in thekidney of a mouse, can remove a large amount of active oxygen or active nitrogen in kidney tubules to relieve and treat acute kidney injury induced by glycerol or cis-platinum, and can be used as a contrast agent for nuclear magnetic resonance imaging and photoacoustic imaging technologies. In addition, the nano-enzyme diagnosis and treatment agent has a good treatment effect and also has excellent biocompatibility and biosafety.

A method for identifying a renal allograft recipient at risk for chronic allograft damage or interstutial fibrosis and tubular atrophy (IF / TA) by comparing the transcription level of a preselected gene signature set with the transcription level of a comparison standard, and diagnosing the recipient as being at risk for chronic allograft damage if the transcription level of the preselected gene signature set is significantly higher than the transcription level of the comparison standard.

Liuwei Dihuang Pill is a Chinese medicinal preparation based on ancient prescription, but alisol, one of its ingredients has the side effect of causing nausea, emesis, dizziness, abdominalgia, myasthenia of limbs and other diseases. By substituting alisol with bark of boxthron-root, the invention provides another Liuwei Dihuang preparation for sustaining the action of body fluid reinforcing and kidney tonifying, and preventing adverse effects of alisol.

The invention relates to the technical field of traditional Chinese medicines, in particular to a medicine for treating renal fibrosis and a preparation method thereof. The 31 traditional Chinese medicinal materials provided by the invention have the effects of anti-renal fibrosis, anti-heart-kidney syndrome, anti-heart failure, anti-nephrotic syndrome and / or anti-renal failure medicines; a composition prepared from rhizoma atractylodis macrocephalae, puffball, lysionotus pauciflorus and periostracum cicadae can inhibit renal tubular cell epithelial-mesenchymal transition and inhibit the transcription level of key genes, and therefore renal fibrosis, heart-kidney syndrome, heart failure, nephrotic syndrome and renal failure can be effectively treated.

The invention relates to the technical field of microfluidics and provides a microfluidic chip and an application thereof. The microfluidic chip comprises an upper substrate, a lower substrate, a first porous membrane and a second porous membrane, wherein a first liquid inlet, a second liquid inlet, a first liquid outlet, a second liquid outlet, a first chamber, a second chamber and a first microchannel are arranged on the upper substrate; the second liquid inlet, the first chamber, the second chamber and the second liquid outlet are sequentially communicated through the first microchannel; the lower substrate is provided with a third liquid inlet, a third liquid outlet, a third chamber, a fourth chamber and a second microchannel, and the third liquid inlet, the third chamber, the fourth chamber and the third liquid outlet are sequentially communicated through a second microchannel. According to the microfluidic chip, the four chambers are formed, upper fluid and lower fluid can be subjected to material exchange twice on porous membranes separating the four chambers, so that the blood purification process of glomerular filtration and tubular secretion and reabsorption of renal units can be simulated with high simulation degree.

The invention relates to a novel application of a niclosamide ethanolamine salt and particularly relates to an application of a niclosamide ethanolamine salt in prevention and treating of type 2 diabetes nephropathy. The protection action and the action mechanism of the niclosamide ethanolamine salt on the type 2 diabetes nephropathy are researched. The result shows that the urinary albumin excretion rate of type 2 diabetes mellitus db / db rats can be reduced by the niclosamide ethanolamine salt, polydipsia and hyperuresis are improved, blood sugar, glycosylated hemoglobin and urine sugar level are reduced, the serum insulin level is improved and the pathological damage of pancreas is improved. By using the niclosamide ethanolamine salt, the pathological damage of glomerulus and kidney tubules can be improved, excretion of urine NAG, NGAL and TGF-beta1 is reduced and activation of a renal cortex mTOR / 4E-BP1 signal channel is inhibited. In addition, the niclosamide ethanolamine salt has a certain protecting effect on liver. In conclusion, the niclosamide ethanolamine salt has a certain protecting effect on type 2 diabetes nephropathy, and the action mechanism is related to inhibition of the mTOR / 4E-BP1 signal channel.

The invention discloses use of NSC228155 in the preparation of a medicine for preventing and treating acute kidney injury, and particularly relates to application of NSC228155 for treating acute renalinjury by protecting renal tubular epithelial cells. NSC228155 can improve the renal function of a cis-platinum-induced acute kidney injury mouse model, improve the pathological changes of acute renal tubular injury, reduce the apoptosis of mouse kidney tissue, reduce the inflammatory response of kidney tissue, and improve the cis-platinum-induced mitochondrial function and oxidative stress status of the mouse renal cortex tissues and renal tubular epithelial cells and protect renal tubular epithelial cells.

The present invention relates to uses of icariin or icariside II, specifically to uses of icariin, icariside II or pharmaceutically acceptable salts thereof in preparation of products for prevention and treatment of kidney diseases, specifically chronic kidney diseases. According to the present invention, with the icariin and the icariside II, the kidney endogenous stem cells of the EdU label can be increased and recruited, the TGF[beta] / Smad, CTGF, P-ERK1 / 2 phosphorylation level can be regulated, the pathological changes of endothelial cells, glomerular basement membrane and kidney tubules can be improved, the proteinuria can be reduced, the urea nitrogen and creatinine clearance level can be improved, the pathological change progression of the chronic kidney disease can be delayed, and the risk of the renal dysfunction can be reduced, such that the icariin and the icariside II can be used for prevention or treatment of kidney diseases.